Development and evaluation of targeting ligand-anchored CNTs as prospective targeted drug delivery system
Source abstract
Abstract
Our main investigation in the present research was to developt and evaluate targeting ligand-anchored multiwalled carbon nanotubes (MWCNTs) as prospective targeted drug delivery system, with a special focus on the MWCNTs surface functionalization (FA-PEG bis-amine functionalized, carboxylated MWCNTs). In vitro release of 5-fluorouracil (5-FU) was studied at pH 7.4 phosphate buffer and 5.5 acetate buffer, which displayed initial faster followed by sustained release up to 900 min. Further, 5-FU/FA-PEG bis amine-MWCNTs was found to be long circulating, prolonged half-life and increased drug accumulation in target tissue.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Carbon Nanotubes in Composites · Graphene and Nanomaterials Applications · Fullerene Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy, Moga, Punjab, India;
Department of Pharmaceutical Sciences, Pharmaceutics Research laboratory, R. H. S. Gour University, Sagar, Madhya Pradesh, India
References (38)
Show source-provided references
1. 10.1016/j.biomaterials.2009.03.01610.1016/j.biomaterials.2009.03.016 ↗
2. 10.1016/j.ejpb.2012.04.00210.1016/j.ejpb.2012.04.002 ↗
3. 10.1038/363605a010.1038/363605a0 ↗
4. 10.1016/S0378-5173(03)00132-710.1016/S0378-5173(03)00132-7 ↗
5. 10.1016/j.biomaterials.2008.05.01610.1016/j.biomaterials.2008.05.016 ↗
6. 10.1021/jp011489110.1021/jp0114891 ↗
7. 10.1021/mp300701e10.1021/mp300701e ↗
8. 10.1016/j.carbon.2008.02.01210.1016/j.carbon.2008.02.012 ↗
9. De la Cruz EF · Int J Electrochem Sci · 2012 · 7 · 357710.1016/S1452-3981(23)13979-4 ↗
10. Hirlekar R · Asian J Pharm Clinl Res · 2009 · 2 · 17
11. 10.1016/j.addr.2011.04.00110.1016/j.addr.2011.04.001 ↗
12. 10.1007/s00339010092910.1007/s003390100929 ↗
13. 10.1038/363603a010.1038/363603a0 ↗
14. 10.1038/354056a010.1038/354056a0 ↗
15. 10.1016/j.nano.2009.03.00110.1016/j.nano.2009.03.001 ↗
16. 10.3109/1061186X.2015.107784610.3109/1061186X.2015.1077846 ↗
17. 10.1016/j.colsurfa.2006.10.02210.1016/j.colsurfa.2006.10.022 ↗
18. 10.3109/1061186X.2012.72921310.3109/1061186X.2012.729213 ↗
19. 10.1590/S1984-8250201300010001310.1590/S1984-82502013000100013 ↗
20. 10.1615/CritRevTherDrugCarrierSyst.v25.i2.2010.1615/CritRevTherDrugCarrierSyst.v25.i2.20 ↗
21. 10.1016/j.drudis.2015.01.00610.1016/j.drudis.2015.01.006 ↗
22. 10.3109/1061186X.2013.81302810.3109/1061186X.2013.813028 ↗
23. 10.1016/j.colsurfb.2015.04.05610.1016/j.colsurfb.2015.04.056 ↗
24. 10.1021/mp500720a10.1021/mp500720a ↗
25. 10.3109/1061186X.2015.105557110.3109/1061186X.2015.1055571 ↗
26. 10.1016/j.drudis.2015.11.01110.1016/j.drudis.2015.11.011 ↗
27. 10.1016/j.biomaterials.2014.02.02210.1016/j.biomaterials.2014.02.022 ↗
28. Mittal V · Int J Pharm Bio Sci · 2010 · 1 · 1
29. 10.3109/1061186X.2012.69716810.3109/1061186X.2012.697168 ↗
30. 10.1016/j.biomaterials.2012.01.02510.1016/j.biomaterials.2012.01.025 ↗
31. Sharma P · Curr Drug Deliv · 2015
32. 10.1021/bm900162410.1021/bm9001624 ↗
33. 10.1021/bc800125u10.1021/bc800125u ↗
34. 10.1039/C5TB02088C10.1039/C5TB02088C ↗
35. 10.3109/21691401.2015.101967010.3109/21691401.2015.1019670 ↗
36. 10.1016/j.biomaterials.2013.09.03610.1016/j.biomaterials.2013.09.036 ↗
37. 10.2174/1874088X0110501024210.2174/1874088X01105010242 ↗
38. 10.1080/1061186090273792010.1080/10611860902737920 ↗